Benralizumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Benralizumab: From Severe Eosinophilic Asthma to Dermatitis
One-Sentence Summary
Benralizumab (Fasenra®) is an anti-IL-5Rα monoclonal antibody approved globally for severe eosinophilic asthma, which depletes eosinophils and basophils via antibody-dependent cell-mediated cytotoxicity (ADCC). The TxGNN model predicts it may be effective for Dermatitis (primarily atopic dermatitis), with 3 directly relevant clinical trials and 20 publications supporting this direction — however, the pivotal Phase 2 RCT (HILLIER study) was terminated early and reported negative results, substantially weakening the clinical case for general atopic dermatitis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe eosinophilic asthma (add-on maintenance treatment in adults) |
| Predicted New Indication | Dermatitis (Atopic Dermatitis) |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L2 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Benralizumab binds with high affinity to IL-5Rα (the alpha subunit of the IL-5 receptor), blocking IL-5 signalling and inducing near-complete, rapid depletion of circulating and tissue eosinophils and basophils via ADCC. Its proven benefit in severe eosinophilic asthma rests precisely on this eosinophil-depleting mechanism — making any eosinophil-driven disease a plausible repurposing target. Currently, detailed MOA data from the DrugBank source is not available in this evidence pack (Data Gap DG002); the above summary is drawn from published literature referenced in the collected trials and publications.
Atopic dermatitis (AD) and eosinophilic asthma share the same upstream inflammatory architecture: ILC2 activation and Th2 skewing drive both conditions, and eosinophils are histologically prominent in AD skin lesions. The IL-5/IL-5Rα axis actively recruits eosinophils to skin, and a 2025 translational study (PMID 40781582) confirmed that Benralizumab does deplete IL-5Rα-bearing cells within AD skin lesions — validating that the drug's mechanism of action physically reaches the target tissue. This mechanistic plausibility is why TxGNN assigned a high prediction score and why two Phase 2 trials were conducted.
However, the clinical results decisively expose the limits of this rationale. AD's core pathological driver is the IL-4/IL-13 axis (not IL-5), which governs epithelial barrier breakdown and keratinocyte dysfunction. Depleting eosinophils without interrupting IL-4/IL-13 signalling is insufficient to resolve AD symptoms — a hypothesis now confirmed by the HILLIER trial's null result. One important exception is DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), a distinct dermatitis subtype where eosinophils are the central pathological mediators; a Phase 2 trial in DRESS (NCT06734884) is planned, representing a narrower but mechanistically better-justified opportunity.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04605094 | Phase 2 | Terminated | 194 | HILLIER study — multinational, randomised, double-blind, placebo-controlled RCT of Benralizumab vs placebo in moderate-to-severe atopic dermatitis. Terminated early; published results (PMID 37178404) confirm no significant effect on AD signs or symptoms. Strongest available evidence — and it is negative. |
| NCT03563066 | Phase 2 | Completed | 20 | Proof-of-concept study in atopic dermatitis evaluating Benralizumab's effects on eosinophils, basophils, and ILC2s in skin. Very small sample (n=20); likely corresponds to the translational findings in PMID 40781582. Mechanistic insights only — cannot support efficacy claim. |
| NCT06734884 | Phase 2 | Not Yet Recruiting | 96 | Benralizumab in DRESS (drug reaction with eosinophilia and systemic symptoms) — eosinophil-centric dermatitis subtype where IL-5Rα inhibition has stronger mechanistic rationale. Estimated completion September 2029; no results yet available. |
| NCT04126499 | N/A (Observational) | Completed | 28 | Retrospective observational study of Benralizumab in severe eosinophilic asthma (Spain individualized access programme). No efficacy assessment; limited real-world safety data only. |
| NCT04763447 | Phase 4 | Recruiting | 234 | Tests Omalizumab (anti-IgE) withdrawal in well-controlled severe allergic asthma — different drug and different target; no direct relevance to Benralizumab or dermatitis. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37178404 | 2023 | Phase 2 RCT Report | JEADV | HILLIER trial primary publication: Benralizumab shows no significant effect on signs and symptoms of moderate-to-severe atopic dermatitis. Primary endpoint not met. Key negative evidence for this indication. |
| 38695680 | 2024 | Phase 2 RCT (Plain Language Summary) | Immunotherapy | Plain-language summary of the HILLIER study confirming the null result; reinforces and disseminates the negative conclusion from the pivotal trial. |
| 40781582 | 2025 | Translational / Mechanistic Study | Clinical and Translational Allergy | Benralizumab depletes IL-5Rα-bearing cells in AD skin lesions — confirms biological target engagement in skin tissue, but clinical benefit (per HILLIER) remains unproven. |
| 39234416 | 2024 | Mechanistic Study | J Allergy Clin Immunol Global | Effect of Benralizumab on skin inflammation after intradermal allergen challenge in AD — provides further mechanistic detail on eosinophil dynamics in the skin. |
| 36411004 | 2023 | Review | Immunology and Allergy Clinics of North America | Reviews biologics (including Benralizumab) for atopic diseases during pregnancy and lactation; relevant for special population safety assessment. |
| 35987486 | 2022 | Safety Review | J Allergy Clin Immunol In Practice | Safety of 7 FDA-approved biologics (including Benralizumab) during pregnancy; summarises maternal and foetal outcome data. |
| 31690400 | 2019 | Review | Allergy and Asthma Proceedings | Reviews immunobiologics for severe asthma, AD, and urticaria; contextualises Benralizumab alongside other anti-IL-5 agents and dupilumab. |
| 36270814 | 2023 | Case Report | Therapie | Benralizumab-induced interstitial granulomatous dermatitis — paradoxical adverse skin reaction reported during asthma treatment; safety signal directly relevant to dermatitis use. |
| 38035014 | 2023 | Pharmacovigilance (FAERS) Study | Frontiers in Pharmacology | Disproportionality analysis identifies a parasitic infection safety signal for anti-type 2 immunity mAbs including Benralizumab — eosinophil depletion may impair helminth defence. |
| 38878020 | 2024 | Observational Study | Journal of Allergy and Clinical Immunology | Patients on Benralizumab, dupilumab, or mepolizumab show reduced post-vaccination SARS-CoV-2 immunity — vaccine response attenuation signal relevant for immunocompromised risk assessment. |
Singapore Market Information
Benralizumab is currently not registered in Singapore. No product authorisations were found in the Health Sciences Authority (HSA) database as of the data cutoff (10 April 2026).
For reference, Benralizumab (Fasenra®) holds regulatory approval in the United States (FDA), European Union (EMA), Japan (PMDA), and multiple other markets for add-on maintenance treatment of severe eosinophilic asthma in adults. Any clinical use in Singapore would require HSA approval, a compassionate use application, or a clinical trial authorisation.
Safety Considerations
Official Singapore/Taiwan package insert warnings and contraindications are not available for this report (Data Gap DG001 — Blocking severity). The following signals are drawn from collected literature only and do not substitute for a formal label review.
- Parasitic infection risk: FAERS pharmacovigilance analysis (PMID 38035014) identified a disproportionate signal for helminth and other parasitic infections across anti-type 2 immunity biologics including Benralizumab. Eosinophil depletion may impair innate anti-helminth defences; patients in endemic regions should be screened and treated for pre-existing helminth infections before initiation.
- Vaccine response attenuation: Patients on Benralizumab showed lower post-vaccination SARS-CoV-2 antibody titres compared to controls (PMID 38878020). Vaccination timing relative to biologic dosing should be considered.
- Paradoxical skin reaction: A case of Benralizumab-induced interstitial granulomatous dermatitis has been reported (PMID 36270814) — a particularly notable signal given the dermatitis indication being evaluated, and potentially relevant to DRESS trial monitoring.
- No drug-drug interactions were identified in the DDI database query (query status: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: The pivotal Phase 2 RCT (HILLIER study, NCT04605094, n=194) was terminated early, and its published results (PMID 37178404) explicitly confirm that Benralizumab produces no significant improvement in moderate-to-severe atopic dermatitis — this constitutes direct, high-quality negative evidence against the primary predicted indication. The underlying biology is now well understood: AD is driven by the IL-4/IL-13 axis, and eosinophil depletion alone is insufficient. The TxGNN model score of 99.16% reflects shared inflammatory pathway membership between asthma and AD at the knowledge-graph level, but does not account for the mechanistic insufficiency revealed by clinical trial data.
A narrow, mechanistically better-justified opportunity exists specifically for DRESS (eosinophil-centric dermatitis subtype), where a Phase 2 trial (NCT06734884, n=96) is planned — but completion is not expected until September 2029 and no interim data are available.
To proceed (for DRESS subtype only), the following is needed:
- Await primary results from NCT06734884 (Phase 2 DRESS trial; estimated September 2029)
- Obtain the official HSA/TFDA package insert to complete the safety assessment (Data Gap DG001 — Blocking)
- Retrieve DrugBank MOA data to complete mechanistic documentation (Data Gap DG002 — High)
- Confirm Singapore regulatory pathway for compassionate use or clinical trial authorisation, given no current HSA registration
- Conduct a focused literature review to identify any AD endotype (e.g., high eosinophil, low IgE) that retains eosinophil dependence and might respond selectively to IL-5Rα inhibition
This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application. All website content should include a YMYL disclaimer.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.